Based on the anti-inflammatory and stabilising effect of the AbM, (Agaricus Blazei Murill) based mushroom extract AndoSanTM on cytokine release in blood in vivo and ex vivo in healthy volunteers after 12 days consumption, the aim in this study is to investigate whether same effect is valid in patients with IBD (inflammatory bowel disease). In addition, calprotectin an abundant cytosolic protein in neutrophils and a surrogate marker for degree of intestinal inflammation will be measured in blood and feces of these patients.
Study Type
INTERVENTIONAL
Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Enrollment
20
AndoSan, 20mlx3, 12 days
Oslo University Hospital, Department of Surgery
Oslo, Norway
The ultimate goal is to see whether the ABM can be used as additional treatment of IBD.
Time frame: 12 days
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.